> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-9/
- Published: 2020-02-09T12:00:00.000Z
- Updated: 2026-09-14T16:02:20.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139755

**Aptevo Therapeutics**, a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, has completed the sale of three of its marketed products (WinRho SDF, HepaGam B, and Varizig) to **Saol Therapeutics** for $74.5 million.

**Mallinckrodt** has acquired **InfaCare Pharmaceutical Corp.**, a privately held specialty pharmaceutical company focused on development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patient populations, for $425 million. If approved, InfaCare's developmental product stannsoporfin is expected to become the first and only pharmacologic option indicated for treating neonates at risk for developing severe jaundice.

**Quest Diagnostics** has agreed to acquire the **Shiel Medical Lab**oratory business from **Fresenius Medical Care** for an undisclosed amount. Shiel is a clinical laboratory provider serving the New York-New Jersey metropolitan area. Fresenius Medical Care’s dialysis-related laboratory services business, Spectra Labs, is not affected by the divestiture.